Highlights

  • Echo IQ has received a Not Substantially Equivalent determination from the FDA regarding its EchoSolv HF submission
  • The company says it maintains a path toward eventual clearance and is weighing several possible regulatory pathways
  • Management states the FDA's concerns relate to statistical analysis rather than the underlying technology
  • Key partnerships involving major cardiac care and diagnostics organisations are described as unaffected by the decision

Echo IQ Limited (ASX:EIQ) has provided an update on the regulatory status of its EchoSolv HF submission after receiving a Not Substantially Equivalent, or NSE, determination from the United States Food and Drug Administration. The Sydney-based company said it continues to see a clear path toward FDA clearance and expects a resolution over the coming quarters.

EchoSolv HF is a cardiac diagnostic software tool associated with echocardiography-based heart failure detection. The FDA's determination relates specifically to the regulatory submission process for the product rather than to a rejection of its underlying purpose or design.

The update comes as part of the company's ongoing effort to bring its diagnostic software to the United States market, where FDA clearance represents a key regulatory milestone for medical device and diagnostic technology companies seeking to commercialise their products. Echo IQ has framed the current NSE determination as one step within a broader process rather than as a final outcome.

Nature of the FDA's Determination

According to Echo IQ, the FDA's concerns arising from the NSE determination were focused narrowly on aspects of statistical analysis within the submission, rather than on the underlying technology or core functionality of the EchoSolv HF device. The company said its own internal assessment has not identified concerns relating to the fundamental technology behind the product.

This distinction is significant in a regulatory context, as an NSE determination tied to statistical methodology in a submission is generally treated differently from one arising out of concerns about a device's core science or safety profile. Echo IQ has sought to emphasise that its response strategy reflects this narrower framing of the regulator's concerns.

Statistical analysis concerns in a device submission often relate to how study data was structured, analysed, or presented to demonstrate equivalence to an existing cleared device, rather than to whether the device itself performs its intended diagnostic function. Echo IQ's characterisation suggests the company believes the underlying clinical and technical basis of EchoSolv HF remains intact, with the current issue instead centred on submission methodology.

Pathways Being Considered

Echo IQ has outlined three possible pathways it is currently evaluating in response to the determination. These include lodging an administrative appeal against the NSE determination, seeking a review through the FDA's Ombudsman process focused on procedural matters, and preparing a new 510(k) submission addressing the specific concerns raised.

The company has not indicated which of these pathways it will ultimately pursue, noting instead that each is being actively considered. Management has reiterated its intention to maintain collaborative engagement with FDA regulators as it works through the available options, framing the current phase as a continuation of an ongoing regulatory dialogue rather than a setback that closes off its clearance prospects.

Each of the three pathways carries a different process and, potentially, a different timeframe. An administrative appeal and an Ombudsman review both work within the existing submission, focusing on procedural or interpretive aspects of the FDA's determination, while a new 510(k) submission would involve preparing fresh materials that directly address the statistical concerns identified. Echo IQ's willingness to weigh all three Options together suggests the company is prioritising the pathway most likely to lead to clearance, rather than committing early to a single approach.

Status of Strategic Partnerships

Echo IQ has stated that its strategic partnerships with Advara HeartCare, Mayo Clinic, and Pro Medicus Limited remain unaffected by the FDA's determination. The company appears keen to reassure Stakeholders that its broader collaborative relationships, which span clinical and technology partners in the cardiac care space, continue on their existing basis regardless of the regulatory timeline for EchoSolv HF in the United States market.

Maintaining these relationships alongside an active regulatory process may allow the company to continue building clinical and commercial familiarity with its diagnostic software while it works through the available pathways toward FDA clearance. Continuity in these arrangements can also be viewed as a signal that collaborators regard the underlying diagnostic approach as sound, independent of the specific regulatory timeline for the United States submission.

Key Insights

Echo IQ's update illustrates a common feature of medical device regulatory pathways in the United States, where a Not Substantially Equivalent determination does not necessarily reflect a fundamental problem with a product's science but can instead relate to specific elements of how a submission was constructed or analysed. The company's characterisation of the issue as centred on statistical analysis, rather than core technology, is central to how it has framed its next steps.

The existence of multiple potential pathways, including an administrative appeal, an Ombudsman review, and a fresh submission, suggests the company retains several routes toward eventual clearance, though the timing and outcome of any of these processes cannot be assumed in advance. Regulatory processes of this nature can take considerable time to resolve, and outcomes are not guaranteed.

For observers following Echo IQ, continued clarity on which regulatory pathway the company chooses to pursue, along with any further updates on its EchoSolv HF submission and its ongoing clinical partnerships, are likely to be the key developments to monitor in the coming quarters.